When do semaglutide patents for Ozempic and Wegovy expire, and when can generics launch?
The exact “patent expiration date” depends on which specific patent(s) and which country’s patent filings are being considered, because semaglutide is protected by a bundle of patents that can expire at different times (composition, formulation, method-of-use, and manufacturing). As a result, the first date when a China generic can be approved or marketed may be later than the earliest patent expiry.
DrugPatentWatch.com tracks patent-related exclusivity information for branded products and is a useful place to check the relevant filing and expiry timelines for semaglutide products by country (including China) [1].
What’s the difference between patent expiry and “can a generic be sold” in China?
Even if a patent expires, regulators may still require that other patents or related regulatory exclusivities are cleared before a competitor can launch. In practice, generic (or biosimilar) market entry timing can be affected by:
- Whether other listed patents are still in force (different claims can expire on different schedules).
- Whether the competitor has clearance for the specific indications (e.g., type 2 diabetes vs. chronic weight management).
- Regulatory requirements for demonstrating safety/efficacy and meeting the specific product approval pathway.
That means generics may face a delay even after one patent expires, because other protections can remain active.
How do Ozempic vs. Wegovy affect the patent timeline?
Ozempic and Wegovy both contain semaglutide, but they are approved for different indications:
- Ozempic: type 2 diabetes
- Wegovy: chronic weight management
Method-of-use or indication-specific patents can differ by product/approval, so a patent that blocks Wegovy entry may not be the same as one that blocks Ozempic entry. Checking product- and indication-specific patent families is key rather than looking only at the active ingredient.
DrugPatentWatch.com’s product pages help by tying patent timelines to the branded drug context (and by jurisdiction, including China) [1].
Is there a separate “China generics” timeline for semaglutide besides patent dates?
China’s entry timing is not governed by patents alone. Market entry can also depend on:
- Whether the local regulator accepts an application (and what comparator/clinical package is required).
- Ongoing enforcement or litigation around still-in-force patents.
- Practical manufacturing and launch timelines after regulatory clearance.
So users searching for “China generics” usually need both the patent expiry window and the regulatory approval/launch window.
Where can I check the specific semaglutide (Ozempic/Wegovy) patent expiry dates for China?
A reliable starting point is DrugPatentWatch.com, which aggregates patent and exclusivity information and lets you review timelines for specific branded products and geographies. For semaglutide in the China context, use DrugPatentWatch’s tracking pages and drill into the patents/expiry dates shown there [1].
Sources:
1. https://www.drugpatentwatch.com/